Skip to main content
SpringerLink
Log in

Management of Acute Promyelocytic Leukemia

  • Chapter
  • First Online:
Acute Myeloid Leukemia

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1194 Accesses

Abstract

With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute promyelocytic leukemia (APL) has become from a detrimental to one of the most curable malignant diseases in humans. In particular, the chemotherapy-free combination regimen with ATO/ATRA has been proven to be advantageous compared to chemotherapy-based treatments in de novo APL and has become standard first-line therapy in non-high-risk APL patients. We here discuss the diagnostic approach, treatment as well as management of complications of patients with APL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E et al (2017) Long-term outcome of acute promyelocytic leukemia treated with all-transretinoic acid, arsenic trioxide, and gemtuzumab. Blood 129:1275–1283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ablain J, de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117:5795–5802

    Article  CAS  PubMed  Google Scholar 

  • Achtari C, Hohlfeld P (2000) Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy. Am J Obstet Gynecol 183:511–512

    Article  CAS  PubMed  Google Scholar 

  • Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B et al (2005) Outcome of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 19:230–233

    Article  CAS  PubMed  Google Scholar 

  • Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A et al (2006) Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24:5703–5710

    Article  PubMed  CAS  Google Scholar 

  • Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S et al (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115:1690–1696

    Article  PubMed  CAS  Google Scholar 

  • Alimoghaddam K, Ghavamzadeh A, Jahani M (2006) Use of NovoSevenR for arsenic trioxide-induced bleeding in PML. Am J Hematol 81:720

    Article  PubMed  Google Scholar 

  • Amant F (2012) Safety of chemotherapy in pregnancy. Clin Adv Hematol Oncol 10:258–259

    PubMed  Google Scholar 

  • Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M et al (2007) A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59–66

    Article  CAS  PubMed  Google Scholar 

  • Au WY, Ma SK, Ooi C, Liang R, Kwong YL (2000) Unusual manifestations of acute leukemia. J Clin Oncol 18:3435–3437

    Article  CAS  PubMed  Google Scholar 

  • Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY et al (2011) Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 118:6535–6543

    Article  CAS  PubMed  Google Scholar 

  • Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M et al (2002) Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 100:3141–3146

    Article  CAS  PubMed  Google Scholar 

  • Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M et al (2011) AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 117:4716–4725

    Article  CAS  PubMed  Google Scholar 

  • Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609–3615

    Article  CAS  PubMed  Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103(4):620–625

    Article  CAS  PubMed  Google Scholar 

  • Breccia M, Carmosino I, Diverio D, De Santis S, De Propris MS, Romano A et al (2003) Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 120:266–270

    Article  PubMed  Google Scholar 

  • Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 93:4131–4143

    Article  CAS  PubMed  Google Scholar 

  • Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S et al (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16:1295–1305

    Article  CAS  PubMed  Google Scholar 

  • Caligiuri MA (1992) Leukemia and pregnancy: treatment and outcome. Adv Oncol 8:10–17

    Google Scholar 

  • Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P et al (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 76:1704–1709

    Article  CAS  PubMed  Google Scholar 

  • Chalmers RJ (1992) Retinoid therapy: a real hazard for the developing embryo. Br J Obstet Gynaecol 99:276–278

    Article  CAS  PubMed  Google Scholar 

  • Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C et al (1991) A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413–1419

    Article  CAS  PubMed  Google Scholar 

  • Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S et al (1990) All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 76:1710–1717

    Article  CAS  PubMed  Google Scholar 

  • Cicconi L, Fenaux P, Kantarjian H, Tallman M, Sanz MA, Lo-Coco F (2018) Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia 32(8):1671–1678

    Article  CAS  PubMed  Google Scholar 

  • Claahsen HL, Semmekrot BA, van Dongen PW, Mattijssen V (1998) Successful foetal outcome after exposure to idarubicin and cytosine-arabinoside during the second trimester of pregnancy-a case report. Am J Perinatol 15:295–297

    Article  CAS  PubMed  Google Scholar 

  • Consoli U, Figuera A, Milone G, Meli CR, Guido G, Indelicato F et al (2004) Acute promyelocytic leukaemia during pregnancy: report of 3 cases. Int J Hematol 79:31–36

    Article  PubMed  Google Scholar 

  • Coombs CC, Tavakkoli M, Tallman MS (2015) Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 5:e304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Culligan DJ, Merriman L, Kell J, Parker J, Jovanovic JV, Smith N et al (2007) The management of acute promyelocytic leukaemia presenting during pregnancy. Clin Leukaemia 1:183–191

    Article  CAS  Google Scholar 

  • de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X et al (2006) Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20:35–41

    Article  PubMed  CAS  Google Scholar 

  • Disperati P, Minden MD, Gupta V, Schimmer AD, Schuh AC, Yee KW et al (2007) Acute promyelocytic leukemia in patients aged 70 years and over—a single center experience of unselected patients. Leuk Lymphoma 48:1654–1658

    Article  PubMed  Google Scholar 

  • Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D et al (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469–3473

    Article  CAS  PubMed  Google Scholar 

  • Fadilah SA, Hatta AZ, Keng CS, Jamil MA, Singh S (2001) Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid. Leukemia 15:1665–1666

    Article  CAS  PubMed  Google Scholar 

  • Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L (1992) All trans-retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 6:64–66

    PubMed  Google Scholar 

  • Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94:1192–1200

    Article  CAS  PubMed  Google Scholar 

  • Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP (1992) The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 117:292–296

    Article  CAS  PubMed  Google Scholar 

  • Frankel SR, Eardley A, Heller G et al (1994) All-trans-retinoic acid for acute promyelocytic leukemia—results of the New-York study. Ann Intern Med 120:278–286

    Article  CAS  PubMed  Google Scholar 

  • Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M et al (2011) Phase II study of single agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753–2757

    Article  CAS  PubMed  Google Scholar 

  • Giagounidis AA, Beckmann MW, Giagounidis AS, Aivado M, Emde T, Germing U et al (2000) Acute promyelocytic leukemia and pregnancy. Eur J Haematol 64:267–271

    Article  CAS  PubMed  Google Scholar 

  • Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M et al (2000) Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-concerted action “molecular cytogenetic diagnosis in haematological malignancies”. Blood 96(4):1297–1308

    CAS  PubMed  Google Scholar 

  • Harrison P, Chipping P, Fothergill GA (1994) Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy. Br J Haematol 86:681–682

    Article  CAS  PubMed  Google Scholar 

  • Helwig A, Klemm M, Schüttig R, Röllig C, Wassilew N, Ehninger G et al (2007) Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk Res 31:703–705

    Article  CAS  PubMed  Google Scholar 

  • Holson JF, Stump DG, Clevidence KJ, Knapp JF, Farr CH (2000) Evaluation of the prenatal developmental toxicity of orally administered arsenic trioxide in rats. Food Chem Toxicol 38:459–466

    Article  CAS  PubMed  Google Scholar 

  • Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572

    Article  CAS  PubMed  Google Scholar 

  • Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120:1570–1580

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ (1987) Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 59:1258–1263

    Article  CAS  PubMed  Google Scholar 

  • Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M et al (2020) Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia 34(9):2333–2341. https://doi.org/10.1038/s41375-020-0758-4. [Epub ahead of print]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X et al (2009) Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 27:2668–2676

    Article  PubMed  Google Scholar 

  • Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U (2007) Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res 31:1585–1597

    Article  CAS  PubMed  Google Scholar 

  • Ko BS, Tang JL, Chen YC, Yao M, Wang CH, Shen MC et al (1999) Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor. Leukemia 13:1406–1408

    Article  CAS  PubMed  Google Scholar 

  • Kühn M, Sammartin K, Nabergoj M, Vianello F (2016) Severe acute axonal neuropathy following treatment with arsenic trioxide for acute promyelocytic leukemia: a case report. Mediterr J Hematol Infect Dis 8:e2016023

    Article  PubMed  PubMed Central  Google Scholar 

  • Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW et al (2002) Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 58:521–526

    Article  CAS  PubMed  Google Scholar 

  • Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R (2001) Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 66:274–279

    Article  CAS  PubMed  Google Scholar 

  • Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837–841

    Article  CAS  PubMed  Google Scholar 

  • Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25:1128–1134

    Article  CAS  PubMed  Google Scholar 

  • Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S et al (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23:2248–2258

    Article  CAS  PubMed  Google Scholar 

  • Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K et al (2013) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol 92:41–52

    Article  PubMed  Google Scholar 

  • Lipovsky MM, Biesma DH, Christiaens GC, Petersen EJ (1996) Successful treatment of acute promyelocytic leukaemia with all-trans-retinoic-acid during late pregnancy. Br J Haematol 94:699–701

    Article  CAS  PubMed  Google Scholar 

  • Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M et al (2016) Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. J Clin Oncol 34:501–508

    Article  CAS  PubMed  Google Scholar 

  • Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121

    Article  CAS  PubMed  Google Scholar 

  • Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y et al (2014) Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Hematol Oncol 32:40–46

    Article  CAS  PubMed  Google Scholar 

  • Lynberg MC, Khoury MJ, Lammer EJ, Waller KO, Cordero JF, Erickson JD (1990) Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance. Teratology 42:513–519

    Article  CAS  PubMed  Google Scholar 

  • Mandelli F, Diverio D, Avvisati G et al (1997) Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and Idarubicin (AIDA) therapy. Blood 90:1014–1021

    CAS  PubMed  Google Scholar 

  • Mandelli F, Latagliata R, Fazi P, Rodeghiero F, Leoni F et al (2003) Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17:1085–1090

    Article  CAS  PubMed  Google Scholar 

  • Mantha S, Tallman MS, Soff GA (2016) What’s new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? Curr Opin Hematol 23:121–126

    Article  CAS  PubMed  Google Scholar 

  • Martínez-Cuadrón D, Montesinos P, Vellenga E, Bernal T, Salamero O, Holowiecka A et al (2018) Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia 32:21–29

    Article  PubMed  CAS  Google Scholar 

  • Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–3262

    Article  CAS  PubMed  Google Scholar 

  • Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J et al (2009a) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775–783

    Article  CAS  PubMed  Google Scholar 

  • Montesinos P, Díaz-Mediavilla J, Debén G, Prates V, Tormo M, Rubio V et al (2009b) Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 94:1242–1249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Norsworthy KJ, Bird T, Avagyan A, Li Y, Akhtar S, Liao J et al (2019) Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-medicare analysis. Blood 134:3497. (abstract)

    Article  Google Scholar 

  • Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M et al (2016) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol 35:605–612

    Article  PubMed  Google Scholar 

  • Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM et al (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751–3757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J et al (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504–510

    Article  CAS  PubMed  Google Scholar 

  • Redner RL (2002) Variations on a theme: the alternate translocations in APL. Leukemia 16(10):1927–1932

    Article  CAS  PubMed  Google Scholar 

  • Reynoso EE, Huerta F (1994) Acute leukaemia and pregnancy-fatal foetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 33:709–710

    CAS  PubMed  Google Scholar 

  • Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112–2117

    Article  CAS  PubMed  Google Scholar 

  • Rosa FW (1983) Teratogenicity of isotretinoin. Lancet 2:513

    Article  CAS  PubMed  Google Scholar 

  • Sanz MA, Montesinos P (2010) Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 125(Suppl 2):S51–S54

    Article  PubMed  Google Scholar 

  • Sanz MA, Montesinos P (2014) How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123:2777–2782

    Article  CAS  PubMed  Google Scholar 

  • Sanz MA, Lo-Coco F, Martín G, Avvisati G, Rayón C, Barbui T et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253

    CAS  PubMed  Google Scholar 

  • Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al (2004a) Risk-adapted treatment of acute promyelocytic leukemia with alltrans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237–1243

    Article  CAS  PubMed  Google Scholar 

  • Sanz MA, Vellenga E, Rayón C, Díaz-Mediavilla J, Rivas C, Amutio E et al (2004b) All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 104:3490–3493

    Article  CAS  PubMed  Google Scholar 

  • Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH et al (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875–1891

    Article  CAS  PubMed  Google Scholar 

  • Sanz MA, Montesinos P, Casale MF, Díaz-Mediavilla J, Jiménez S, Fernández I et al (2015) Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia. Ann Hematol 94:1357–1361

    Article  CAS  PubMed  Google Scholar 

  • Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133(15):1630–1643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W (2003) New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102(8):2746–2755

    Article  CAS  PubMed  Google Scholar 

  • Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S et al (2005) Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 82:224–229

    Article  CAS  PubMed  Google Scholar 

  • Siu BL, Alonzo MR, Vargo TA, Fenrich AL (2002) Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer 12:399–402

    Article  CAS  PubMed  Google Scholar 

  • Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL et al (2006) Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 108:103–106

    Article  CAS  PubMed  Google Scholar 

  • Stentoft J, Nielsen JL, Hvidman LE (1994) All-trans retinoic acid in acute promyelocytic leukemia in late pregnancy. Leukemia 8:1585–1588

    CAS  PubMed  Google Scholar 

  • Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edn. WHO Press, Geneva

    Google Scholar 

  • Tallman MS (2007) Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 20:57–65

    Article  PubMed  Google Scholar 

  • Tallman MS, Kwaan HC (1992) Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543–553

    Article  CAS  PubMed  Google Scholar 

  • Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021–1028

    Article  CAS  PubMed  Google Scholar 

  • Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298–4302

    Article  CAS  PubMed  Google Scholar 

  • Terada Y, Shindo T, Endoh A, Watanabe M, Fukaya T, Yajima A (1997) Foetal arrhythmia during treatment of pregnancy-associated acute promyelocytic leukaemia with all-trans retinoic acid and favorable outcome. Leukemia 11:454–455

    Article  CAS  PubMed  Google Scholar 

  • Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R et al (2004) Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 124:610–617

    Article  PubMed  Google Scholar 

  • Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA et al (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849

    Article  CAS  PubMed  Google Scholar 

  • Verma V, Giri S, Manandhar S, Pathak R, Bhatt VR (2016) Acute promyelocytic leukemia during pregnancy: a systematic analysis of outcome. Leuk Lymphoma 57:616–622

    Article  CAS  PubMed  Google Scholar 

  • Warrell RP, Maslak P, Eardley A et al (1994) Treatment of acute promyelocytic leukemia with all-trans-retinoic acid—an update of the New-York experience. Leukemia 8:929–933

    PubMed  Google Scholar 

  • Williams SF, Schilsky RL (2000) Antineoplastic drugs administered during pregnancy. Semin Oncol 27:618–622

    CAS  PubMed  Google Scholar 

  • Yamakura M, Tsuda K, Ugai T, Sugihara H, Nisihida Y, Takeuchi M et al (2014) High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia. Acta Haematol 131(2):76–77

    Article  CAS  PubMed  Google Scholar 

  • Yang D, Hladnik L (2009) Treatment of acute promyelocytic leukaemia during pregnancy. Pharmacotherapy 29(6):709–724

    Article  PubMed  Google Scholar 

  • Zhang Y, Zhang Z, Li J, Li L, Han X, Han L et al (2013) Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 119:115–125

    Article  CAS  PubMed  Google Scholar 

  • Zhu H, Hu J, Chen L, Zhou W, Li X, Wang L et al (2016) The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood 128:1525–1528

    Article  CAS  PubMed  Google Scholar 

  • Zver S, Andoljsek D, Cernelc P (2004) Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 72:455–456

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

    Sabine Kayser & Uwe Platzbecker

  2. German Cancer Research Center (DKFZ), Heidelberg, Germany

    Sabine Kayser

Authors
  1. Sabine Kayser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe Platzbecker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Kayser .

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus, Dresden, Germany

    Christoph Röllig

  2. Department of Haematology, Amsterdam University Medical Center location VUMC, Amsterdam, Noord-Holland, The Netherlands

    Gert J. Ossenkoppele

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kayser, S., Platzbecker, U. (2021). Management of Acute Promyelocytic Leukemia. In: Röllig, C., Ossenkoppele, G.J. (eds) Acute Myeloid Leukemia . Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-72676-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-72676-8_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-72675-1

  • Online ISBN: 978-3-030-72676-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation